Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.

Date publication

mars 2026

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François

Tous les auteurs :
Strickler JH, Raimbourg J, Cohen JE, Ghiringhelli F, Sharma MR, Kitagawa C, Lee KH, O'Neil B, de Miguel M, Saada-Bouzid E, Li R, Rudra-Ganguly N, Luo A, Parikh A, Morrison-Thiele G, Neagu Aristide M, Hunter Z, Burns M, Kuboki Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41910595

Résumé

Gastrointestinal tumors, including esophageal and gastric/gastroesophageal junction adenocarcinoma (GEA), have a high mortality rate and present significant treatment challenges. Telisotuzumab adizutecan (Temab-A; ABBV-400), a novel antibody-drug conjugate targeting c-Met protein (also known as MET protein), has shown encouraging results in patients with advanced GEA.

Référence

Clin Cancer Res. 2026 03 30;: